Summary:
A Phase 3, Randomized, Double-blind,
Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in
Moderate-to-Severe Major Depressive Disorder
Qualified Participants Must:
• Are between the ages of 18–74 years
•
Have symptoms of depression or have been diagnosed with major depressive disorder (MDD)
•
Are currently experiencing a depressive episode
Qualified Participants May Receive:
Those who qualify to take part in the study may be reimbursed for study participation.